Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
Eligible age
18–69 yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goals of this clinical study are to first learn more about safety and dosing of the study drug GS-4321 in healthy participants. The study will then learn about the safety and effectiveness of GS-4321 in participants with chronic hepatitis delta (CHD). The primary objective of Phase 1 of this study is to evaluate the safety, tolerability and Pharmacokinetics (PK) of the escalating single doses of GS-4321 administered in healthy participants. The primary objective of Phase 2 of this study is to evaluate the efficacy and safety of the multiple escalating doses of GS-4321 in participants with CHD.
Sponsor: Gilead Sciences
Where it's recruiting
Source: ClinicalTrials.gov · NCT07096193 · last updated 2026-06-11